Finance

Lists
Why is DEVA down 2,16%?
Dive Deeper
DEVA:IST
Deva Holding AS
79,20 TRY
-2,16%
(-1,75) 1D
14-окт., 18:10:00 GMT+3  ·   TRY
All symbols
SymbolPriceChange% Change
Generating top insights for DEVA...
Open
80,80 TRY
High
80,80 TRY
Low
78,55 TRY
Mkt. cap
15,84 млд
Avg. vol.
634,66 миң
Volume
357,36 миң
52-wk high
109,30 TRY
52-wk low
57,50 TRY
EPS
-4,21 TRY
Shares outstanding
200,02 млн
No. of employees
3 миң
Open
80,80 TRY
High
80,80 TRY
Low
78,55 TRY
Mkt. cap
15,84 млд
Avg. vol.
634,66 миң
Volume
357,36 миң
52-wk high
109,30 TRY
52-wk low
57,50 TRY
EPS
-4,21 TRY
Shares outstanding
200,02 млн
No. of employees
3 миң
News stories
From web sources and news partners
Profile
DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements. A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas. As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
About Deva Holding AS
CEO-
Employees3,06 миң
Founded1958-ж., 22-сен.
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in TRY
Loading Previous Earnings...
Revenue
Net income
All values in TRY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
4,47 млд
5,49 млд
6,33 млд
6,00 млд
Cost of goods sold
3,02 млд
3,84 млд
4,10 млд
2,82 млд
Cost of revenue
3,02 млд
3,84 млд
4,10 млд
2,82 млд
Research and development expenses
264,29 млн
174,34 млн
361,82 млн
480,63 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,30 млд
1,58 млд
1,60 млд
1,68 млд
Operating expense
1,55 млд
1,74 млд
1,93 млд
2,07 млд
Total operating expenses
4,58 млд
5,58 млд
6,03 млд
4,89 млд
Operating income
-102,14 млн
-89,10 млн
293,59 млн
1,11 млд
Other non operating income
337,87 млн
185,09 млн
663,10 млн
-172,42 млн
EBT including unusual items
-137,34 млн
-340,89 млн
585,37 млн
527,53 млн
EBT excluding unusual items
-137,34 млн
-362,51 млн
586,40 млн
527,53 млн
Income tax expense
-116,52 млн
1,00 млд
682,64 млн
-86,52 млн
Effective tax rate
84,84%
-294,28%
116,62%
-16,40%
Other operating expenses
-9,80 млн
-11,48 млн
-34,86 млн
-88,91 млн
Net income
-20,81 млн
-1,34 млд
-97,27 млн
614,05 млн
Net profit margin
-0,47%
-24,48%
-1,54%
10,23%
Earnings per share
-
-
-
-
Interest and investment income
59,54 млн
23,47 млн
114,43 млн
157,88 млн
Interest expense
-617,63 млн
-656,70 млн
-542,37 млн
-662,77 млн
Net interest expenses
-558,09 млн
-633,23 млн
-427,95 млн
-504,88 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
237,92 млн
622,26 млн
701,87 млн
1,42 млд
Gain or loss from assets sale
-15,06 млн
-15,93 млн
-32,28 млн
-12,59 млн
AI content may include mistakes. Learn more
Google колдонмолору